Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-03-24
2009-06-23
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S138100, C424S143100, C424S144100, C424S152100, C424S178100, C424S185100, C424S192100, C424S193100, C424S198100, C530S324000, C530S350000, C530S387300, C530S388220, C530S388700, C530S388730, C530S388800, C530S388850
Reexamination Certificate
active
07550143
ABSTRACT:
The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different. The disclosed methods and compositions provide a facile and general way to obtain homodimers, homotetramers and heterotetramers of virtually any functionality and/or binding specificity.
REFERENCES:
patent: 4046722 (1977-09-01), Rowland
patent: 4699784 (1987-10-01), Shih et al.
patent: 5770198 (1998-06-01), Coller et al.
patent: 6261537 (2001-07-01), Klaveness et al.
patent: 6524854 (2003-02-01), Monia et al.
patent: 2003/0198956 (2003-10-01), Makowski et al.
patent: 2003/0232420 (2003-12-01), Braun et al.
patent: 2004/0018587 (2004-01-01), Makowski et al.
patent: 2005/0003403 (2005-01-01), Rossi et al.
patent: 2006/0228300 (2006-10-01), Chang et al.
patent: 2007/0086942 (2007-04-01), Chang et al.
patent: 2007/0140966 (2007-06-01), Chang et al.
patent: WO200068248 (2000-11-01), None
patent: WO2007075270 (2007-07-01), None
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
Ngo et al, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.
Winkler et al, J Immunology 165: 4505-4514, 2000.
Banky et al, J Biol Chem 273(52): 35048-35055, 1998.
Zhu et al, Investigational New Drugs 17: 195-212, 1999.
Chang et al, Clin Cancer Res 13(18 Suppl): 5586s-5591s, Sep. 15, 2007.
Mason et al, Molecular Endocrinology 8(3): 325-332, 1994.
Anonymus, Google search for the term “7E3”, Aug. 13, 2008.
Oyen et al, FEBS Letters 246(1-2): 57-64, Mar. 1989.
Banky et al. “Related Protein-Protein Interaction Modules Present Drastically Different Surface Topographies Despite A Conserved Helical Platform”. J. Mol. Biol. (2003) 330, 1117-1129.
Chang et al. “The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity”, Clin Cancer Res Sep. 15, 2007;13(18 Suppl), pp. 5586-5591.
Rossi et al. “Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting”. Proc Natl Acad Sci Epub Apr. 24, 2006, vol. 103, No. 18, pp. 6841-6846.
Alto et al. “Bioinformatic design of A-kinase anchoring protein-in silico: A potent and selective peptide antagonist of type II protein kinase A anchoring,” Proceedings of the National Academy of Science, Apr. 15, 2003, vol. 100, No. 8, pp. 4445-4450 [online]. [Retrieved on Feb. 19, 2007]. [Retrieved from the internet: http://www.pnas.org/cgi/reprint/100/8/4445].
Banky et al. “Dimerization/Docking Domain of the Type lα Regulatory Subunit of cAMP-dependent Protein Kinase”, J. Biol. Chem. 273:35048-55, 1998.
Carr et al., “Interaction of the Regulatory Subunit (RII) of cAMP-dependent Protein Kinase with RII-anchoring Proteins Occurs through an Amphipathic Helix Binding Motif”, J. Biol. Chem. 266:14188-92 (1991).
Colledge et al. “AKAPs: from structure to function”, Trends Cell Biol. 6:216-21 (1999).
Corbin et al. “Regulation of Adenosine 3′,5′-Monophosphate-dependent Protein Kinase”, J. Biol. Chem. 248:1813-21 (1973).
Gold et al. “A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma”, Cancer Res. 68:4819-26, 2008.
Gillies et al. “High-level expression of chimeric antibodies using adapted cDNA variable region cassettes”, J. Immunol. Methods 125 (1989) 191-202.
Goldenberg et al. “Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting”, J. Nucl. Med. 49:158-63, 2008.
Hausken et al. “Mutational Analysis of the A-Kinase Anchoring Protein (AKAP)-binding Site on RII”, J. Biol. Chem. 271:29016-22 (1996).
Hodneland et al. “Selective immobilization of proteins to self-assembled monolayers presenting active site-directed capture ligands”, Proc. Natl. Acd. Sci. USA 2002; 99:5048-5052.
Lohmann et al. “High-affinity binding of the regulatory subunit (RII) of cAMP-dependent protein kinase to microtubule-associated and other cellular proteins”, Proc. Natl. Acad. Sci. USA 81:6723-27 (1984).
Mason, Anthony J. “Functional Analysis of the Cysteine Residues of Activin A”, Mol. Endocrinol. 8:325-32, 1994.
Newlon et al. “A Novel Mechanism of PKA Anchoring Revealed by Solution Structures of Anchoring Complexes”, EMBO J. 2001; 20:1651-1662.
Newlon et al. “The molecular basis for protein kinase A anchoring revealed by solution NMR”, Nature Struct. Biol. 1999; 3:222-227.
Ngo et al. “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”, The Protein Folding Problem and Tertiary Structure Prediction, Ch. 14, pp. 491-495, (Mertz & Le Grand, Eds.), Birkhauser Boston, 1994.
Oyen et al. “Human testis cDNA for the regulatory subunit RIIα of cAMP-dependent protein kinase encodes an alternate amino-terminal region”, FEBS Letters 246:57-64, 1989.
Rose et al. “Structural basis of dimerization, coactivator recognition and MODY3 mutations in HNF-1α”, Nature Struct. Biol. 2000; 7:744-748.
Rossi et al. “Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics”, Cancer Res. 68:8384-92, 2008.
Rustandi et al. “The Ca2+-Dependent Interaction of S100B (ββ) with a Peptide Derived from p53”, Biochemistry 1998; 37: 1951-1960.
Scott et al. “Type II Regulatory Subunit Dimerization Determines the Subcellular Localization of the cAMP-dependent Protein Kinase”, J. Biol. Chem. 265:21561-66 (1990).
Sharkey et al. “Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody”, Cancer Res. 68:5282-90, 2008.
Sharkey et al. “Metastatic Human Colonic Carcinoma: Molecular Imaging with Pretargeted SPECT and PET in a Mouse Model”, Radiology 246:497-507, 2008.
Stryer et al. “Levels of Structure in Protein Architecture”, Biochemistry, 3rd Ed., pp. 31-33, W.H. Freeman & Co., New York, 1988.
Winkler et al. “Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody”, J. Immunol. 165:4505-14, 2000.
Wong et al. “AKAP Signalling Complexes: Focal Points in Space and Time”, Nat. Rev. Mol. Cell Biol. 12:959-70 (2004).
Zhu et al. “Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor”, Invest. New Drugs 17:195-212, 1999.
Chang Chien Hsing
Goldenberg David M.
McBride William J.
Rossi Edmund A.
Huynh Phuong
IBC Pharmaceuticals, Inc.
Nakashima Richard A.
LandOfFree
Methods for generating stably linked complexes composed of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for generating stably linked complexes composed of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for generating stably linked complexes composed of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4146146